Lentigen Vector Used in Landmark Cancer Clinical Study


University of Pennsylvania Researchers used a lentiviral vector designed and manufactured by Lentigen to genetically modify "Serial Killer" T-cells to obliterate tumors in patients with Chronic Lymphocytic Leukemia . Further information on this study can be found at: http://www.uphs.upenn.edu/news/News_Releases/2011/08/t-cells/.
 
 
 
Background_footer
© Copyright 2008 Lentigen Corp. All Rights Reserved.    + Privacy Policy    + Terms of Use